Related by context. All words. (Click for frequent words.) 72 AP# [003] 72 perifosine 70 Amrubicin 69 BAY #-# 68 obatoclax 68 satraplatin 68 axitinib 68 Marqibo 67 ganetespib 67 IMGN# 67 T DM1 67 alvespimycin 67 tanespimycin 66 PXD# 66 ixabepilone 66 Carfilzomib 66 Phase Ib 66 XL# [003] 66 RG# [001] 66 OncoVEX GM CSF 66 Vectibix 66 ASA# 66 relapsed multiple myeloma 65 Treanda 65 phase IIb clinical 65 picoplatin 65 brentuximab vedotin 65 Proteolix 65 MGCD# [001] 65 SCH # 65 HGS# 65 refractory multiple myeloma 65 HuMax CD4 65 FTY# 65 PLX# 65 amrubicin 65 Nexavar ® 65 FOLOTYN 65 JAK inhibitor 65 Actemra 65 Perifosine 65 Abraxane 65 VELCADE 65 Phenoptin 65 pomalidomide 65 VEGF Trap 65 INCB# [001] 65 AEG# 64 SAR# [004] 64 panitumumab 64 Xcytrin 64 Advexin 64 Folotyn 64 aflibercept 64 Bortezomib 64 tamibarotene 64 vandetanib 64 investigational compound 64 elotuzumab 64 CoFactor 64 clofarabine 64 daclizumab 64 Velcade 64 mipomersen 64 sapacitabine 64 OXi# 64 Phase Ib clinical 64 relapsed refractory multiple myeloma 64 oral ridaforolimus 64 PF # [001] 64 Onyx Pharma 64 Allovectin 7 63 Velcade bortezomib 63 Phase III clinical 63 phase IIb 63 ipilimumab 63 Phase 1b 63 ridaforolimus 63 Revlimid 63 Nexavar 63 tivozanib 63 Phase Ib study 63 eltrombopag 63 temsirolimus 63 pralatrexate 63 Erbitux 63 bendamustine 63 Satraplatin 63 sorafenib 63 ofatumumab 63 lintuzumab 63 proteasome inhibitor 63 Dapagliflozin 63 dirucotide 63 TRISENOX 63 Alpharadin 63 indolent NHL 63 TREANDA 63 TELCYTA 63 HuMax CD# 63 Targretin 63 XmAb# 63 Mylotarg 63 phase Ib 63 Revlimid lenalidomide 63 glufosfamide 63 enzastaurin 63 ISIS # 63 Telaprevir 62 Ceplene 62 Jevtana 62 ponatinib 62 PARP inhibitor 62 dacetuzumab 62 cediranib 62 Laquinimod 62 valopicitabine 62 ONX 62 oral proteasome inhibitor 62 Sprycel 62 neratinib 62 docetaxel chemotherapy 62 IMC A# 62 Cloretazine R VNP#M 62 HuMax EGFr 62 ocrelizumab 62 mertansine 62 Yervoy 62 pertuzumab 62 PEG SN# 62 Fodosine 62 Zalbin 62 omacetaxine 62 Fx #A 62 ONCONASE 62 TELINTRA 62 Tarceva 62 GRN#L 62 Dacogen 62 ADVEXIN 62 vemurafenib 62 teriflunomide 62 CR# vcMMAE 62 huN# DM1 62 telaprevir 62 cilengitide 62 Allovectin 7 ® 62 OPAXIO 62 Phase IIa trials 62 Azedra 62 PEG PAL 62 sorafenib tablets 62 L BLP# 62 INCB# [002] 62 Sym# 62 Onco TCS 62 deforolimus 62 oral prodrug 62 NVA# 62 RDEA# 62 Phase 2b clinical 61 bortezomib 61 phase IIa clinical 61 Zolinza 61 Phase 2b trial 61 CD# antibody [001] 61 HGS ETR1 61 LymphoStat B 61 Phase Ib II 61 maribavir 61 paclitaxel Taxol ® 61 ambrisentan 61 brentuximab vedotin SGN 61 Phase 2b study 61 relapsing remitting multiple sclerosis 61 fidaxomicin 61 #D#C# 61 CA4P 61 palifosfamide 61 celgosivir 61 registrational 61 Cimzia 61 nab paclitaxel 61 dalbavancin 61 Tamibarotene 61 Tarceva erlotinib 61 voreloxin 61 EOquin TM 61 Cloretazine ® 61 anticancer agent 61 huC# DM4 61 sunitinib malate 61 eniluracil 61 ProLindac 61 pegfilgrastim 61 dasatinib 61 atacicept 61 forodesine 61 tesetaxel 61 LAF# 61 Azixa 61 vascular disrupting agent 61 Asentar 61 docetaxel Taxotere R 61 entinostat 61 metastatic melanoma 61 Phase 2a trial 61 thymalfasin 61 oritavancin 61 PRT# 61 Xyotax 61 telbivudine 61 Phase IIa clinical 61 mTOR inhibitor 61 Allovectin 7 R 61 vorinostat 61 abiraterone acetate 61 Phase 1b trial 61 sunitinib 61 Vidaza 61 Ixempra 61 temozolomide 61 Phase 2a 61 Troxatyl 61 Traficet EN 61 Tarvacin 61 metastatic renal cell carcinoma 60 Pixantrone 60 Cimzia ® 60 visilizumab 60 PEG Interferon lambda 60 capecitabine Xeloda R 60 mapatumumab 60 Avastin bevacizumab 60 Panzem 60 Mozobil 60 ELACYT 60 VIDAZA 60 RGB # 60 radiation sensitizer 60 metaglidasen 60 Annamycin 60 Bezielle 60 HER2 positive metastatic breast 60 LY# [003] 60 Xanafide 60 galiximab 60 alvimopan 60 DXL# 60 angiogenesis inhibitor 60 ZYBRESTAT 60 AEGR 60 Aplidin 60 TMC# [001] 60 KRN# 60 chronic myeloid leukemia CML 60 Corlux 60 belinostat 60 rNAPc2 60 ceftaroline 60 imetelstat 60 Onrigin 60 Phase 2a clinical 60 lapatinib 60 evaluating tivozanib 60 iniparib 60 Sorafenib 60 eculizumab 60 Zerenex 60 phase IIb trial 60 zalutumumab 60 anticancer compound 60 bevacizumab Avastin 60 vilazodone 60 MOZOBIL 60 Vandetanib 60 BCX# 60 romidepsin 60 generation proteasome inhibitor 60 pazopanib 60 HQK 60 subcutaneous formulation 60 Viramidine 60 Zactima 60 Entereg 60 SCCHN 60 rituximab Rituxan 60 Dasatinib 60 TNFerade 60 Pazopanib 60 TYKERB 60 Taxotere ® 60 afatinib 60 MBP# [001] 60 EOquin 60 Dacogen injection 60 NGX# 60 CBLC# 60 GALNS 60 Hycamtin 60 azacitidine 60 Boceprevir 60 sorafenib Nexavar ® 60 metastatic colorectal cancer 60 Amigal 60 Cotara 60 TG# [001] 60 FavId 60 Phase III 60 abiraterone 60 IDX# 60 advanced NSCLC 60 Hematide 59 refractory Hodgkin lymphoma 59 vinorelbine 59 Reolysin 59 ProSavin 59 MEK inhibitors 59 Mipomersen 59 Erbitux cetuximab 59 Taxotere R 59 Gemcitabine 59 cutaneous T cell 59 Phase IIa 59 tesmilifene 59 Imprime PGG 59 linaclotide 59 Riquent 59 Cloretazine 59 Insegia 59 Rituxan 59 Onconase 59 Telavancin 59 FOLOTYN ® 59 refractory PTCL 59 adecatumumab 59 dose cohorts 59 Rituxan rituximab 59 pegylated interferons 59 dose escalation trial 59 YONDELIS 59 MabCampath 59 Panzem R NCD 59 Herceptin trastuzumab 59 ZOLINZA 59 pivotal Phase III 59 PSMA ADC 59 Ceflatonin 59 HGS ETR2 59 dose cohort 59 lapatinib Tykerb 59 trastuzumab DM1 T DM1 59 figitumumab 59 tafamidis 59 HspE7 59 ATL/TV# 59 decitabine 59 taxane 59 virus HCV protease inhibitor 59 gefitinib 59 Neulasta ® 59 histone deacetylase HDAC inhibitor 59 OMAPRO 59 SNT MC# 59 alogliptin 59 Zensana TM 59 laquinimod 59 randomized Phase 59 olaparib 59 vosaroxin 59 BENLYSTA 59 Torisel 59 LBH# 59 investigational drug 59 phase IIa 59 multiple myeloma 59 REVLIMID 59 Civacir 59 refractory gout 59 Aflibercept 59 Genasense 59 regorafenib 59 Aurora kinase inhibitor 59 viral kinetic 59 AQ4N 59 methylnaltrexone 59 ATL# [001] 59 CD# monoclonal antibody 59 Phase III trials 59 Phase 1b clinical 59 Sutent 59 Virulizin R 59 otelixizumab 59 initiate Phase 1b 59 IMA# 59 Nexavar sorafenib 59 nilotinib 59 sorafenib Nexavar 59 Arranon 59 Quinamed 59 trabectedin 59 Proxinium TM 59 Avastin 59 erlotinib Tarceva 59 Clolar 59 Fludara 59 ELND# 59 ZK EPO 59 Omnitarg 59 alemtuzumab 59 bifeprunox 59 DAVANAT 59 Pertuzumab 59 Ranexa 59 Evoltra TM 59 Doxil 59 Panitumumab 59 regadenoson 59 MGd 59 relapsed refractory 59 HCV protease inhibitor 59 immunotherapeutic agent 59 Taxotere docetaxel 59 talactoferrin 59 ISENTRESS 59 TG# [003] 59 Tarceva TM 59 registrational trial 59 CTCE 59 Atiprimod 59 vicriviroc 59 Phase IIIb clinical 59 NSCLC 59 Alocrest 59 febuxostat 59 thalidomide Thalomid 59 receptor tyrosine kinase inhibitor 59 farletuzumab 59 motesanib 58 Daclizumab 58 liposomal formulation 58 PLK1 SNALP 58 evaluating Xcytrin 58 Ventavis 58 nitazoxanide 58 Ambrisentan 58 MyVax 58 Leukine 58 hematological malignancies 58 Phase IIb trials 58 metastatic HRPC 58 TACI Ig 58 ONTAK 58 PDE4 inhibitor 58 lixisenatide 58 PSN# [002] 58 Omacetaxine 58 recurrent glioblastoma 58 Afinitor 58 MDV# 58 PEG INTRON 58 CDP# 58 recurrent ovarian cancer 58 Telcyta 58 rilonacept 58 denosumab 58 erlotinib 58 gefitinib Iressa 58 Evoltra 58 CYC# 58 Antegren 58 lumiliximab 58 RSR# 58 omacetaxine mepesuccinate 58 ENMD 58 PHX# 58 Alzhemed TM 58 investigational humanized monoclonal antibody 58 cancer immunotherapies 58 GVAX 58 odanacatib 58 AeroLEF TM 58 Vilazodone 58 AVN# [001] 58 rindopepimut 58 oral formulation 58 Phase IIb clinical 58 biologic therapy 58 durable remissions 58 Seliciclib 58 bafetinib 58 Tavocept 58 Fampridine SR 58 Voreloxin 58 integrase inhibitor 58 Phase #b/#a 58 romiplostim 58 Urocidin 58 BiovaxID 58 glatiramer acetate 58 Tykerb 58 TEMODAL 58 crizotinib 58 Oncophage 58 bazedoxifene 58 phase 2a 58 bortezomib Velcade R 58 refractory chronic lymphocytic 58 Symadex 58 chronic lymphocytic leukemia CLL 58 chemotherapy regimens 58 EndoTAG TM -1 58 PDX pralatrexate 58 muraglitazar 58 gemcitabine 58 HuLuc# 58 multicenter Phase 58 CBLB# 58 Alvesco R 58 NP2 Enkephalin 58 Archexin 58 panitumumab Vectibix 58 cangrelor 58 JANUVIA 58 CIMZIA TM 58 HCD# [002] 58 Gemzar ® 58 preclinical 58 Mepact 58 anticancer therapy 58 pradefovir 58 dose escalation Phase 58 CYT# 58 PROMACTA 58 Genentech Roche 58 tyrosine kinase inhibitor 58 anti TNF 58 Tocosol Paclitaxel 58 Campath 58 midstage trials 58 Locteron 58 teduglutide 58 Phase 2b 58 Arcalyst 58 follicular NHL 58 Tyrima 58 hematological cancers 58 Pemetrexed 58 zileuton 58 MEK inhibitor 58 investigational pan BCR 58 docetaxel Taxotere 58 MAGE A3 ASCI 58 REOLYSIN ® 58 recurrent NSCLC 58 APF# 58 antitumor activity 58 Glufosfamide 58 Relistor 58 TOCOSOL Paclitaxel 58 Opexa 58 TYSABRI 58 Virulizin ® 58 mycophenolate mofetil 58 Cladribine Tablets 58 erlotinib Tarceva ® 58 relapsing multiple sclerosis 58 Nanobody 58 ARRY 58 placebo controlled Phase 58 Phase IIb trial 58 anticancer agents 58 cetuximab Erbitux 58 ongoing Phase 1b 58 protease inhibitor 58 standard chemotherapy regimen 58 bavituximab 58 QAB# 58 OvaRex ® MAb 58 Plicera 58 lorvotuzumab mertansine 58 confirmatory Phase III 58 nimotuzumab 58 boceprevir 58 capecitabine Xeloda 58 orally bioavailable 58 ZACTIMA 58 CHOP chemotherapy 58 bortezomib Velcade 58 bicifadine 58 Fibrillex TM 58 DASISION 58 docetaxel 58 Chemophase 58 docetaxel Taxotere ® 58 DU #b 58 MAXY G# 58 PROSTVAC TM 57 Cloretazine R 57 custirsen 57 protein kinase inhibitor 57 trastuzumab Herceptin 57 ZEVALIN 57 pixantrone 57 exenatide 57 dimebon 57 Genz # 57 reslizumab 57 Phase IIb clinical trials 57 zanolimumab 57 Phase IIb 57 Lacosamide 57 GW# [003] 57 phase IIb study 57 seliciclib 57 Golimumab 57 FOLFIRI 57 #I TM# 57 elacytarabine 57 chemotherapeutic agent 57 LEP ETU 57 perampanel 57 subcutaneously administered 57 relapsed ovarian cancer 57 Reverset 57 Revimmune 57 danoprevir 57 Phase III clinical trials 57 Phase IIa trial 57 IAP inhibitors 57 AGGRASTAT ® 57 BRAF inhibitor 57 Bronchitol 57 PNP inhibitor 57 Zelrix 57 daptomycin 57 PRX # 57 DPP4 inhibitor 57 bortezomib Velcade ® 57 Celgene Revlimid 57 AZILECT R 57 tremelimumab 57 ABRAXANE 57 ORENCIA R 57 Phase III pivotal 57 BEXXAR 57 torezolid phosphate 57 platinum refractory 57 kinase inhibitors 57 CCR5 antagonist 57 trastuzumab DM1 57 XYOTAX 57 Albuferon 57 INGN 57 Aptivus 57 Tesetaxel 57 PREOS 57 SUTENT 57 golimumab 57 Combidex 57 carboplatin paclitaxel 57 corticosteroid dexamethasone 57 Amplimexon 57 Pirfenidone 57 hormone refractory prostate cancer 57 BRIM2 57 albinterferon alfa 2b 57 pegylated interferon alpha 57 YERVOY 57 peginesatide 57 Votrient 57 cabazitaxel 57 bardoxolone 57 iSONEP 57 StaphVAX 57 Kuvan 57 proteasome inhibitors 57 Stedivaze 57 confirmatory clinical 57 Cimzia TM 57 Evoltra ® 57 Trastuzumab 57 ANA# 57 BARACLUDE R 57 DAVANAT R 57 NKTR 57 oral antiviral 57 Zybrestat 57 Bicifadine 57 Naproxcinod 57 Firazyr 57 Vectibix panitumumab 57 oral anticoagulant 57 Natalizumab 57 Specifid 57 refractory CTCL 57 Benlysta belimumab 57 superficial bladder cancer 57 Serdaxin 57 dose escalation 57 HDAC inhibitor 57 HCV protease inhibitors 57 B CLL 57 PrevOnco 57 veltuzumab 57 MLN# 57 INT# [002] 57 Rituximab 57 mCRC 57 NXL# 57 CIMZIA ™ 57 Rhucin ® 57 BYDUREON 57 Irinotecan 57 Prestara 57 HRPC 57 pirfenidone 57 investigational protease inhibitor 57 diabetic neuropathic pain 57 ThermoDox ® 57 Tasigna nilotinib 57 Debio 57 gemcitabine chemotherapy 57 tocilizumab 57 TriRima 57 mRCC 57 brentuximab 57 Clevudine 57 Genasense ® 57 KNS # 57 darinaparsin 57 selective androgen receptor modulator 57 raltegravir 57 bapineuzumab 57 MuGard 57 ACZ# 57 lupus nephritis 57 TORISEL 57 darusentan 57 Mpex 57 rFIXFc 57 Orencia 57 histamine dihydrochloride 57 GLPG# 57 PD LID 57 STELARA 57 tezampanel 57 IRESSA 57 IIa trial 57 betrixaban 57 Icatibant 57 gastrointestinal stromal tumors GIST 57 assessing T DM1 57 R sorafenib tablets 57 anti leukemic 57 Zevalin 57 leukemia CLL 57 rituximab 57 Phase 1a clinical 57 iclaprim 57 ASONEP 56 EFAPROXYN 56 velaglucerase alfa 56 vidofludimus 56 PREOS R 56 BRIM3 56 Cimzia R 56 Maraviroc 56 MAXY alpha 56 Gleevec imatinib mesylate 56 atypical antipsychotic 56 ruxolitinib 56 Nuvion 56 MAP# 56 Rexin G 56 PEG interferon 56 Phase 1a 56 interferon beta 1b 56 cetuximab Erbitux ® 56 apaziquone 56 heterozygous FH 56 cytotoxic chemotherapy 56 SRT# [003] 56 ACTEMRA TM 56 Remodulin 56 dacarbazine 56 Tanespimycin 56 generation purine nucleoside 56 dasatinib Sprycel ® 56 Erlotinib 56 Restanza 56 CRx 56 vismodegib 56 eribulin mesylate 56 aflibercept VEGF Trap 56 MGCD# [002] 56 cell lung cancer 56 Promacta 56 paclitaxel Taxol 56 Synvisc One 56 clevudine 56 GRN# 56 orBec 56 refractory indolent non 56 seliciclib CYC# 56 Lialda 56 metastatic CRC 56 Alkeran 56 pitavastatin 56 blinatumomab 56 investigational monoclonal antibody 56 Fampridine 56 ERBITUX 56 Aplidin R 56 cell lymphoma CTCL 56 BENLYSTA ® 56 talabostat 56 Iressa 56 Lapatinib 56 pegloticase 56 investigational hepatitis C 56 multi kinase inhibitor 56 volociximab 56 SPRYCEL ® 56 blinded randomized placebo controlled 56 ZD# [001] 56 Romidepsin 56 boosted protease inhibitor 56 proteasome inhibitor bortezomib 56 solid tumors 56 rALLy trial 56 FOLFOX chemotherapy 56 Ceflatonin R 56 Vorinostat 56 taxanes 56 interferon therapy 56 Aryplase 56 refractory NSCLC 56 sitagliptin 56 ITMN 56 sipuleucel T 56 darapladib 56 cisplatin chemotherapy 56 molecularly targeted 56 BIBW 56 Elotuzumab 56 lymphoma CTCL 56 chemotherapeutic drug 56 multiple myeloma MM 56 preclinical studies 56 tolevamer 56 IRX 2 56 Teysuno 56 randomized controlled Phase 56 LEVADEX 56 elesclomol 56 Yondelis 56 VQD 56 R#/MEM # 56 doripenem 56 vinflunine 56 Alemtuzumab 56 OncoVEX 56 Maribavir 56 TLK# 56 ofatumumab HuMax CD# 56 PARP inhibitors 56 MT# MEDI 56 oral rivaroxaban 56 Mycograb 56 RSD# 56 acyclovir Lauriad R 56 peg IFN 56 relapsed SCLC 56 pivotal Phase 56 G CSF 56 lenalidomide Revlimid R 56 topotecan 56 Epratuzumab 56 CLORETAZINE TM VNP#M 56 systemic ALCL 56 refractory metastatic colorectal cancer 56 LY# [002] 56 linagliptin 56 oncology indications 56 MIRCERA 56 cetuximab 56 CAELYX 56 Onalta 56 confirmatory Phase 3 56 GV# [001] 56 Tasigna 56 plus dexamethasone 56 Tarvacin TM 56 castration resistant prostate cancer 56 ENMD # 56 OHR/AVR# 56 MEK inhibitor RDEA# 56 INC# 56 Targretin capsules 56 bevacizumab Avastin ® 56 PhosLo 56 ISF# 56 Pfizer Sutent 56 Phase Ib clinical trials 56 Zenvia 56 Pralatrexate 56 Abiraterone acetate 56 multicenter Phase II 56 dexpramipexole 56 fipamezole 56 IMC #B 56 XL# XL# XL# 56 humanized anti 56 Orathecin 56 Orazol 56 4SC 56 ANG# 56 ocular formulation 56 aclidinium bromide 56 pan HDAC inhibitor 56 Canvaxin 56 bevacizumab 56 randomized Phase III 56 CCX# 56 relapsed myeloma 56 Oral NKTR 56 SARMs 56 SILENOR TM 56 Rebif ® 56 Gleevec resistant 56 TBC# 56 follicular non 56 DORIBAX 56 ACTEMRA 56 ADXS# 56 Marketing Authorization Application 56 Numax 56 VELCADE melphalan 56 LHRH antagonist 56 aleglitazar 56 Belinostat 56 GATTEX 56 IMiDs 56 telaprevir VX 56 chemotherapeutic regimen 56 NEBIDO 56 leukemia AML 56 BNC# 56 dapagliflozin 56 triphendiol 56 refractory CLL 56 Replagal 56 IND submission 56 APPRAISE 56 surrogate endpoint 56 novel anticancer 56 TREDAPTIVE 56 Exenatide 56 Raptiva ® 56 PTK ZK 56 tasocitinib 56 lesinurad 56 miconazole Lauriad 56 ospemifene 56 anticancer therapies 56 Neuvenge 56 metastatic hormone refractory 56 Santhera 56 GSK# [001] 56 VEGF inhibitors 56 diagnosed multiple myeloma 56 humanized monoclonal antibody 56 INTELENCE 56 Evoltra R 56 MK #B 56 Triapine 56 AVE# 56 trastuzumab 56 refractory APL 56 exenatide once 56 iloperidone 56 oxymorphone ER 56 cancer neuroendocrine tumor 56 Sebivo 56 AzaSite Plus 56 Tekturna HCT 56 Phase #/#a 56 opioid induced bowel dysfunction 56 Vion Pharmaceuticals 56 hepatocellular carcinoma HCC 56 L MTP PE 56 paclitaxel poliglumex 56 posaconazole 55 Exherin TM 55 rhThrombin 55 cetuximab Erbitux R 55 resistant ovarian cancer 55 Ocrelizumab